HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

British Journal of Cancer

Volumn 110, Issue 5, 2014, Pages 1169-1178

  Liu, Y J ^a   Shen, D ^b   Yin, X ^a   Gavine, P ^a   Zhang, T ^a   Su, X ^a   Zhan, P ^a   Xu, Y ^a   Lv, J ^a   Qian, J ^a   Liu, C ^a   Sun, Y ^a   Qian, Z ^a   Zhang, J ^a   Gu, Y ^a   Ni, X ^b  

^a ASTRAZENECA   (United Kingdom)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastric cancer; Growth factor receptors; Personalised medicine; Predictive markers; Targeted therapies

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANTINEOPLASTIC AGENT; AZD 4547; CRIZOTINIB; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LAPATINIB; MOLECULAR MARKER; SCATTER FACTOR RECEPTOR; SGC 031; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE FGFR2; ONCOGENE MET; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL TIME; TUMOR XENOGRAFT; ANIMAL CELL; GENE EXPRESSION; GENE TARGETING; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINAZOLINES; RANDOM ALLOCATION; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895807143     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.61     Document Type: Article

References (40)

1. Asaoka Y, Ikenoue T, Koike K (2011) New targeted therapies for gastric cancer. Expert Opin Investig Drugs 20(5): 595-604.
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697.
3. Brunetto AT, Kristeleit RS, de Bono JS (2010) Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncol 6(8): 1339-1352.
4. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR (2012) MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 11(3): 660-669.
5. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6(8): 2209-2219. (Pubitemid 47294749)
6. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61(5): 673-684.
7. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15(7): 2207-2214.
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917.
9. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59(6): 795-805. (Pubitemid 46440603)
10. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29(36): 4789-4795.
11. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 23(10): 2656-2662.
12. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14): 2137-2150. (Pubitemid 46655601)
13. Khushalani NI (2012) Phase I and II clinical trials for gastric cancer. Surg Oncol Clin N Am 21(1): 113-128.
14. Kim JW, Im SA, Kim M, Cha Y, Lee KH, Keam B, Kim MA, Han SW, Oh DY, Kim TY, Kim WH, Bang YJ (2012) The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res 32(4): 1547-1553.
15. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B (2008) FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 68(7): 2340-2348. (Pubitemid 351521808)
16. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107(2): 325-333.
17. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29(36): 4803-4810.
18. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14(6): 490-499.
19. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y (2012) FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106(4): 727-732.
20. Meza-Junco J, Sawyer MB (2012) Metastatic gastric cancer - focus on targeted therapies. Biologics 6: 137-146.
21. Ming SC (1998) Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer 1(1): 31-50.
22. Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska-Arlukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczynska-Kloda M, Tempinska-Szalach A, Rossi E, Varella-Garcia M (2012) Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 107(5): 793-799.
23. Nadauld LD, Ford JM (2013) Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol 31(7): 838-839.
24. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8(6): 215.
25. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K (2006) A novel molecular targeting compound as K-samII/ FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131(5): 1530-1541. (Pubitemid 44708935)
26. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30): 3968-3976.
27. Oliner K, Tang R, Anderson A, Lan Y, Iveson T, Donehower R, Jiang Y, Dubey S, Loh E (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30(Suppl): abstr 4005.
28. Oliveras-Ferraros C, Corominas-Faja B, Cufi S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, Lopez-Bonet E, Martin AG, Menendez JA (2012) Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 11(21): 4020-4032.
29. Pazo Cid RA, Anton A (2013) Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol 85(3): 350-362.
30. Power DG, Kelsen DP, Shah MA (2010) Advanced gastric cancer-slow but steady progress. Cancer Treat Rev 36(5): 384-392.
31. Rodig S, Sequist LV, Schiller JH, Chen Y, Halim A, Waghorne C, Zahir H, Schwartz B. An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study [Abstract] (2012) Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 March 31-April 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012; 72(8 Suppl): Abstract nr 1729. doi:1538-7445.AM2012-1729.
32. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws Jr TF, Hudson-Curtis BL, Gilmer TM (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40(4): 580-594. (Pubitemid 47063294)
33. Shan L, Ying J, Lu N (2013) HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol 8: 76.
34. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, Liu JP, Bu H, Zhou XY, Du X (2013) HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 24(9): 2360-2364.
35. Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3(1 Suppl): S21-S35.
36. Timofeevski SL, McTigue MA, Ryan K, Cui J, Zou HY, Zhu JX, Chau F, Alton G, Karlicek S, Christensen JG, Murray BW (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48(23): 5339-5349.
37. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Clement-Duchene C, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Zha J, Pandita A, Yu W, Yauch RL, Patel PH, Peterson AC (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29(Suppl): abstr 7505.
38. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2): 116-129.
39. Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14(6): 481-489.
40. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Ji J, Gavine PR, Zhang J, Kilgour E, Ji Q (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19(9): 2572-2583.